Rodríguez-Medina B, Blanes M, Vinaixa C, Aguilera V, Rubín Á, Prieto M, Berenguer M

Language: English
References: 20
Page: 974-978
PDF size: 86.77 Kb.

ABSTRACT

Haemophagocytic syndrome (HS) is a rare disease that is often fatal despite treatment. HS is characterized by fevers, lymphadenopathy, hepatosplenomegaly, cytopenias and hyperferritinaemia due to deregulated activation and proliferation of macrophages, leading to uncontrolled phagocytosis of platelets, erythrocytes, lymphocytes, and their hematopoietic precursors throughout the reticuloendothelial system. Mycobacterium tuberculosis-associated HS is a rare and underdiagnosed association with only 39 cases reported. We describe a case of HS associated with disseminated Mycobacterium tuberculosis in the setting of post-liver transplantation anti-hepatitis C therapy with pegylated interferon (pegIFN), ribavirin (RBV) and telaprevir (TVR). Despite the delay in the etiologic diagnosis, the patient was treated properly with corticosteroids, cyclosporine and tuberculostatic agents. It is unknown whether telaprevir, a drug that only recently has been started off-label in liver transplant recipients, may have contributed to the development of the HS. Unfortunately, as in many reported cases of HS, the outcome was unfavourable resulting in the death of the patient.

REFERENCES

1. Rouphael NG, Talati NJ, Vaughan C, et al. Infections associated with haemophagocytic syndrome. The Lancet infectious diseases 2007; 7: 814-22.

2. Brastianos PK, Swanson JW, Torbenson M, et al: Tuberculosis- associated haemophagocytic syndrome. The Lancet infectious diseases 2006; 6: 447-54.

3. Wong CK, Wong BC, Chan KC, et al. Cytokine profile in fatal human immunodeficiency virus tuberculosis Epstein- Barr virus associated hemophagocytic syndrome. Archives of internal medicine 2007; 167: 1901-3.

4. Verbsky JW, Grossman WJ. Hemophagocytic lymphohistiocytosis: diagnosis, pathophysiology, treatment, and future perspectives. Annals of Medicine 2006; 38: 20-31.

5. Risdall RJ, McKenna RW, Nesbit ME, et al. Virus-associated hemophagocytic syndrome: a benign histiocytic proliferation distinct from malignant histiocytosis. Cancer 1979; 44: 993-1002.

6. Cacoub P, Bourliere M, Lubbe J, et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatology 2012; 56: 455-63.

7. McGowan CE, Fried MW. Barriers to hepatitis C treatment. Liver Int 2012; 32(Suppl. 1): 151-6.

8. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.

9. Lin KH, Hsu PI, Yu HC, et al. Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet counts. BMC Gastroenterology 2012; 12: 7.

10. Gelb AM, Brazenas N, Sussman H, et al. Acute granulomatous disease of the liver. American Journal of Digestive diseases 1970; 15: 842-7.

11. Gibson JA. Granulomatous liver disease and portal hypertension. Proceedings of the Royal Society of Medicine 1973; 66: 502-3.

12. Flamm SL. Granulomatous liver disease. Clinics in liver disease 2012; 16: 387-96.

13. Vakiani E, Hunt KK, Mazziotta RM, et al. Hepatitis C-associated granulomas after liver transplantation: morphologic spectrum and clinical implications. Am J Clin Pathol 2007; 127: 128-34.

14. Hurst EA, Mauro T. Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature. Arch Dermatol 2005; 141: 865-8.

15. Aggarwal P, Kumar G, Dev N, et al. Haemophagocytic lymphohistiocytosis: a cause for rare but fatal outcome in tuberculosis. BMJ case reports 2012; 2012.

16. Numakura T, Matsuura Y, Takiguchi H, et al. Tuberculosis associated with hemophagocytic syndrome complicated by treatment with infliximab. Nihon Kokyuki Gakkai Zasshi 2010; 48: 449-53.

17. Baraldes MA, Domingo P, Gonzalez MJ, et al. Tuberculosisassociated hemophagocytic syndrome in patients with acquired immunodeficiency syndrome. Arch Intern Med 1998; 158: 194-5.

18. Ruiz-Arguelles GJ, Arizpe-Bravo D, Garces-Eisele J, et al. Tuberculosis-associated fatal hemophagocytic syndrome in a patient with lymphoma treated with fludarabine. Leukemia & lymphoma 1998; 28: 599-602.

19. Levitsky J, Fiel MI, Norvell JP, Wang E, Watt KD, Curry MP, Tewani S, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology 2012; 142: 1132-9, e1131.

20. Selzner N, Guindi M, Renner EL, Berenguer M. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol 2011; 55: 207-17.